Moxaverine

Source: Wikipedia, the free encyclopedia.
Moxaverine
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • 1-Benzyl-3-ethyl-6,7-dimethoxyisoquinoline
JSmol)
  • CCC1=NC(=C2C=C(C(=CC2=C1)OC)OC)CC3=CC=CC=C3
  • InChI=1S/C20H21NO2/c1-4-16-11-15-12-19(22-2)20(23-3)13-17(15)18(21-16)10-14-8-6-5-7-9-14/h5-9,11-13H,4,10H2,1-3H3 ☒N
  • Key:MYCMTMIGRXJNSO-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Moxaverine has been used in therapy based on the direct vasodilatory effect of the drug, a phosphodiesterase inhibitor,[1] and on its influence on the rheological properties of red blood cells.[2]

Moxaverine hydrochloride (Kollateral forte®, Ursapharm. Saarbrücken, Germany) has been shown to increase ocular blood flow in patients with age-related macular degeneration, primary open angle glaucoma, and to increase choroidal and retrobulbar blood flow in elderly patients with eye diseases associated with hypo-perfusion.[3] The ocular efficacy of moxaverine has been explored in the clinic.[4]

References

  1. PMID 2854468
    .
  2. PMID 3415714
    .
  3. S2CID 3269602
    .
  4. ^ Clinical trial number NCT01629680 for "A Randomized, Placebo-controlled Study Investigating the Effects of Moxaverine on Ocular Blood Flow After Oral Administration in Healthy Subjects" at ClinicalTrials.gov
gastrointestinal system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Moxaverine&oldid=1147903656"